Citigroup’s Tvardi Therapeutics TVRD Stock Holding History

Citigroup’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-61	Closed	-$33K	–	7588
2020 Q4	$33K	Hold	61	–	–	﹤0.01%	6336
2020 Q3	$28K	Hold	61	–	–	﹤0.01%	5964
2020 Q2	$38K	Sell	61 -83	-58%	-$45.8K	﹤0.01%	6196
2020 Q1	$69K	Sell	144 -520	-78%	-$283K	﹤0.01%	5673
2019 Q4	$385K	Buy	664 +133	+25%	+$93.3K	﹤0.01%	4653
2019 Q3	$349K	Sell	531 -527	-50%	-$438K	﹤0.01%	4673
2019 Q2	$819K	Buy	1,058 +511	+93%	+$359K	﹤0.01%	3884
2019 Q1	$387K	Sell	547 -295	-35%	-$177K	﹤0.01%	4458
2018 Q4	$394K	Sell	842 -114	-12%	-$73.5K	﹤0.01%	4383
2018 Q3	$824K	Buy	956 +89	+10%	+$64.3K	﹤0.01%	3718
2018 Q2	$597K	Buy	867 +34	+4%	+$17.3K	﹤0.01%	3900
2018 Q1	$371K	Buy	833 +50	+6%	+$24.3K	﹤0.01%	4302
2017 Q4	$345K	Buy	783 +719	+1,123%	+$328K	﹤0.01%	4496
2017 Q3	$31K	Buy	+64	New	+$32K	﹤0.01%	6244

Other funds holding TVRD

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AFG

American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DWAM

Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Citigroup's TVRD Position: Q2 2026 in Review

Citigroup reduced its Tvardi Therapeutics (TVRD) stake by 100% in Q2 2026, selling an estimated $862 and leaving 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #5652.

Citigroup first reported a position in TVRD in Q2 2014 and has held it in 48 quarters since. The position peaked at $3.88M in Q4 2018. 57 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

Citigroup held 1 share of Tvardi Therapeutics worth $2 as of Q2 2026.
Citigroup sold 275 Tvardi Therapeutics shares in Q2 2026, an estimated $862.
Tvardi Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5652 holding.
Citigroup first reported a position in Tvardi Therapeutics in Q2 2014 and has held it in 48 quarters since.
Citigroup's Tvardi Therapeutics position peaked at $3.88M in Q4 2018.
57 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.